TABLE 3.
Cumulative change in other ocular measures from baseline
| Visit | Estimated marginal means (95%CI) | p‐value | |
|---|---|---|---|
| Placebo | 0.01% atropine | ||
| Ocular biometrics | |||
| Anterior chamber depth (mm) | |||
| 6 months | 0.025 (0.004–0.046)* | 0.016 (0.002–0.030)* | 0.50 |
| 12 months | 0.020 (−0.002 to 0.041) | 0.038 (0.023–0.052)** | 0.18 |
| 18 months | 0.025 (0.003–0.047)* | 0.046 (0.031–0.060)** | 0.13 |
| 24 months | 0.026 (0.003–0.049)* | 0.044 (0.030–0.059)** | 0.018 |
| Central corneal radius (mm) | |||
| 6 months | −0.004 (−0.011 to 0.004) | −0.004 (−0.009 to 0.001) | 0.99 |
| 12 months | 0.001 (−0.007 to 0.009) | −0.001 (−0.006 to 0.005) | 0.76 |
| 18 months | 0.000 (−0.008 to 0.008) | 0.006 (0.001–0.011)* | 0.22 |
| 24 months | 0.008 (0.000 to −0.016)* | 0.008 (0.003–0.013)** | 0.94 |
| Lens thickness (mm) a | |||
| 24 months | 0.042 (0.013–0.070)** | 0.052 (0.035–0.070)** | 0.53 |
| Central corneal thickness (μm) a | |||
| 24 months | 0.110 (−3.060 to 3.280) | 0.360 (−1.570 to 2.300) | 0.90 |
| Pupillary measures | |||
| Constriction latency (ms) | |||
| 6 months | 0.012 (0.003–0.021)** | 0.018 (0.012–0.024)** | 0.31 |
| 12 months | 0.004 (−0.005 to 0.014) | 0.016 (0.010–0.022)** | 0.047 |
| 18 months | 0.006 (−0.003 to 0.016) | 0.018 (0.012–0.024)** | 0.034 |
| 24 months | 0.012 (0.003–0.022)* | 0.016 (0.010–0.022)** | 0.59 |
| Constriction velocity (mm s−1) b | |||
| 6 months | 0.090 (−0.056 to 0.24) | 0.280 (0.180–0.38)** | 0.035 |
| 12 months | −0.030 (−0.190 to 0.13) | 0.330 (0.240–0.43)** | <0.001 |
| 18 months | −0.020 (−0.170 to 0.14) | 0.260 (0.160–0.36)** | 0.003 |
| 24 months | 0.030 (−0.130 to 0.19) | 0.220 (0.120–0.32)** | 0.044 |
| Dilation velocity (mm s−1) | |||
| 6 months | −0.003 (−0.079 to 0.074) | 0.047 (−0.004 to 0.097) | 0.29 |
| 12 months | 0.072 (−0.012 to 0.16) | 0.043 (−0.010 to 0.095) | 0.56 |
| 18 months | 0.050 (−0.031 to 0.13) | 0.034 (−0.018 to 0.086) | 0.75 |
| 24 months | −0.030 (−0.110 to 0.055) | 0.032 (−0.020 to 0.084) | 0.22 |
| Amplitude (mm) c | |||
| 6 months | −0.11 (−0.23 to 0.01) | −0.39 (−0.47 to −0.31)** | <0.001 |
| 12 months | −0.047 (−0.17 to 0.08) | −0.45 (−0.53 to 0.37)* | <0.001 |
| 18 months | −0.07 (−0.20 to 0.06) | −0.42 (−0.50 to −0.35)** | <0.001 |
| 24 months | −0.19 (−0.31 to −0.06)** | −0.37 (−0.45 to −0.29)* | 0.015 |
| Other ocular measures | |||
| Distance BCVA (logMAR) | |||
| 6 months | 0.01 (−0.01 to 0.02) | −0.02 (−0.04 to −0.01)** | 0.010 |
| 12 months | −0.02 (−0.04 to 0.00) | −0.04 (−0.05 to −0.02)** | 0.13 |
| 18 months | −0.02 (−0.04 to −0.01)* | −0.04 (−0.05 to −0.03)** | 0.21 |
| 24 months | −0.03 (−0.05 to −0.01)** | −0.04 (−0.05 to −0.03)** | 0.52 |
| Near BCVA (logMAR) | |||
| 6 months | −0.03 (−0.05 to −0.01)** | −0.03 (−0.04 to −0.02)** | 0.85 |
| 12 months | −0.04 (−0.06 to −0.02)* | −0.03 (−0.04 to −0.02)** | 0.37 |
| 18 months | −0.01 (−0.04 to 0.01) | −0.01 (−0.03 to 0.00) | 0.84 |
| 24 months | −0.03 (−0.06 to −0.01) | −0.03 (−0.04 to −0.02)** | 0.65 |
| Accommodative amplitude (D) | |||
| 6 months | −0.77 (−1.74 to 0.20) | −2.04 (−2.67 to −1.41)** | 0.033 |
| 12 months | −0.18 (−1.18 to 0.82) | −2.04 (−2.68 to −1.39)** | 0.003 |
| 18 months | −0.53 (−1.54 to 0.48) | −2.56 (−3.20 to −1.91)** | 0.001 |
| 24 months | −1.38 (−2.41 to −0.34)** | −2.70 (−3.34 to −2.05)** | 0.039 |
| Stereoacuity (arcmin) a | |||
| 24 months | 5.9 (−13.4 to 25.2) | 13.7 (1.9–25.5)* | 0.50 |
Note: Asterisks indicate statistical difference from baseline at *p < 0.05 and **p < 0.01. p‐values in bold represent significant group difference at p < 0.05. All analyses corrected for age and baseline measures.
Abbreviation: BCVA, best‐corrected visual acuity; CI, confidence interval.
a
Only measured at baseline and 24 months.
b
More negative values representing faster constriction velocity.
c
Difference between maximum and minimum pupil diameter.